Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Barst, D. Miller, F. Beery, M. McGoon (New York, San Francisco, Rochester, United States Of America). Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry. Eur Respir J 2011; 38: Suppl. 55, 2384

Member's Comments

No comment yet.

Related content which might interest you: REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Prognostic risk factors of disease worsening in patients with functional class II pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry Source: Eur Respir J, 55 (5) 1901747; 10.1183/13993003.01747-2019 Year: 2020 Impact of the state of endothelium on clinical and functional parameters in COPD patients with arterial hypertension. Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017 Predictive factors of clinical worsening in functional class II patients with pulmonary arterial hypertension (PAH) in the EARLY trial of bosentan Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2012; 39: 589-596 Year: 2012 Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Survival and prognostic factors in patients with incident systemic sclerosis-associated pulmonary arterial hypertension from the French registry Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 A critical analysis of survival in pulmonary arterial hypertension Source: Eur Respir Rev 2012 21:218-222 Year: 2012 Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 emPHasis-10 score predicts mortality in patients with pulmonary hypertension Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Impact of two 5-year anticoagulant strategies on survival and echocardiographic parameters in the patients with chronic thromboembolic pulmonary hypertension (CTEPH) who did not undergo pulmonary endarterectomy Source: Annual Congress 2004 - Pulmonary embolism Year: 2004 Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Survival in pulmonary hypertension in Spain: insights from the Spanish registry}, Source: Eur Respir J 2012; 40: 596-603 Year: 2012 Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry Source: Eur Respir J, 58 (2) 2101483; 10.1183/13993003.01483-2021 Year: 2021